These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 17267342

  • 1. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
    Bast DJ, Dresser L, Duncan CL, Walker SE, Mandell LA, Low DE, de Azavedo JC.
    J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
    [Abstract] [Full Text] [Related]

  • 2. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
    Azoulay-Dupuis E, Bédos JP, Mohler J, Moine P, Cherbuliez C, Peytavin G, Fantin B, Köhler T.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1046-54. PubMed ID: 15728901
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M, Parra A, García-Calvo G, Ponte C, Giménez MJ, Aguilar L, Soriano F.
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [Abstract] [Full Text] [Related]

  • 4. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M, Giménez MJ, Vicente D, Aguilar L, Pérez-Trallero E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [Abstract] [Full Text] [Related]

  • 5. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
    MacGowan AP, Bowker KE.
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1096-100. PubMed ID: 12604547
    [Abstract] [Full Text] [Related]

  • 7. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
    Azoulay-Dupuis E, Bédos JP, Mohler J, Peytavin G, Isturiz R, Moine P, Rieux V, Cherbuliez C, Péchère JC, Fantin B, Köhler T.
    Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
    Edelstein PH, Shinzato T, Doyle E, Edelstein MA.
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2204-9. PubMed ID: 11451675
    [Abstract] [Full Text] [Related]

  • 9. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
    Garrison MW, Schimmels JA, Madaras-Kelly KJ.
    Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 11. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
    Endimiani A, Brigante G, Bettaccini AA, Luzzaro F, Grossi P, Toniolo AQ.
    BMC Infect Dis; 2005 Nov 24; 5():106. PubMed ID: 16307682
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN, Fritsche TR, Sader HS.
    Diagn Microbiol Infect Dis; 2005 Jun 24; 52(2):129-33. PubMed ID: 15964501
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
    Fukuda Y, Takahata M, Mitsuyama J.
    J Infect Chemother; 2006 Feb 24; 12(1):1-8. PubMed ID: 16506083
    [Abstract] [Full Text] [Related]

  • 14. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
    Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ.
    J Infect Dis; 2001 Sep 15; 184(6):794-8. PubMed ID: 11517444
    [Abstract] [Full Text] [Related]

  • 15. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM, Andes DR.
    Pharmacotherapy; 2005 May 15; 25(5):717-40. PubMed ID: 15899734
    [Abstract] [Full Text] [Related]

  • 16. Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia.
    De Azavedo JC, Dresser L, Duncan CL, Walker SE, Low DE, Bast DJ.
    J Chemother; 2007 Aug 15; 19(4):392-7. PubMed ID: 17855183
    [Abstract] [Full Text] [Related]

  • 17. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J, Hovde LB, Simonson D, Rotschafer JC.
    Diagn Microbiol Infect Dis; 2008 Feb 15; 60(2):155-61. PubMed ID: 17910998
    [Abstract] [Full Text] [Related]

  • 18. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L, Sevillano D, Martínez-Marín C, López-Casla MT, Gracia M, Alou L, del Carmen Ponte M, Prieto J, Soriano F, Spanish Pneumococcal Infection Study Network (G03/103).
    Int J Antimicrob Agents; 2006 Apr 15; 27(4):294-9. PubMed ID: 16527462
    [Abstract] [Full Text] [Related]

  • 19. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P.
    J Antimicrob Chemother; 2004 Sep 15; 54(3):640-7. PubMed ID: 15317743
    [Abstract] [Full Text] [Related]

  • 20. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Sep 15; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.